Eli Lilly shares jumped in the last month as investors gained confidence in its pipeline of products.
1 extracted signal · 0 resolved · 1 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 10 Oct 2025, 15:45 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
AI-generated source summary
The analysis primarily focuses on Eli Lilly's (LLY) strong financial performance and future prospects. The video highlights that LLY stock outperformed the S&P 500 by 12.2% recently. Key metrics discussed include strong operating profit margins and impressive returns on invested capital, currently at 29% and improving from 11.5% in 2016. The company's pipeline is also highlighted, citing new treatments for early-stage breast cancer and upcoming oral weight loss treatments expected in the next year. A fair value is calculated to be $1315.55, compared to a current market price of $845.72, therefore it is still undervalued. The forward P/E ratio is stated to be at 31.0.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.